Showing results (101-110 of 152) with videos related to
Sort By:
Pageof 16
The New England Journal of Medicine|January 17, 2014
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1Kris V Kowdley, Eric Lawitz, Fred Poordad, et al.Hepatology (Baltimore, Md.)|September 12, 2017
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trialRohit Loomba, Eric Lawitz, Parvez S Mantry, et al.Plos One|May 30, 2013
A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infectionDavid Gardiner, Jay Lalezari, Eric Lawitz, et al.Medicine|April 28, 2025
The accuracy of FibroScan, FIB-4, and nonalcoholic fatty liver disease fibrosis score in predicting biopsy-defined fibrosis and steatosis across all fibrosis stages in patients with metabolic dysfunction associated steatotic liver diseaseKeerthi Thallapureddy, David Twitchell, Kristen Ott, et al.Gastroenterology|June 15, 2016
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and SofosbuvirChristoph Sarrazin, Hadas Dvory-Sobol, Evguenia S Svarovskaia, et al.Journal of Viral Hepatitis|May 21, 2019
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6Eric Lawitz, Edward Gane, Jordan J Feld, et al.The Lancet. Gastroenterology & Hepatology|June 13, 2020
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label studyEric Lawitz, Charles S Landis, Steven L Flamm, et al.Hepatology (Baltimore, Md.)|June 22, 2010
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infectionAndrew J Muir, Mitchell L Shiffman, Atif Zaman, et al.Hepatology (Baltimore, Md.)|December 26, 2015
Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)Eric Lawitz, Gary Matusow, Edwin DeJesus, et al.Journal of Viral Hepatitis|February 11, 2019
Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infectionEric Lawitz, Fred Poordad, Leah J Anderson, et al.Pageof 16